Front Matter Free
-
Published:2021
Robert J. Nordstrom, "Front Matter", Quantitative Imaging in Medicine: Applications and Clinical Translation, Robert J. Nordstrom
Download citation file:
Quantitative Imaging in Medicine: Applications and Clinical Translation presents a detailed exploration of the potential applications of quantitative imaging. This timely book provides a thorough introduction to the applications of quantitative imaging standards and tools in various imaging modalities as well as individual organ sites. It is the first book-length compendium to focus on the clinical adaption and translational potential of novel imaging methods.
This important book:
Addresses the pathways of clinical translation, particularly as it relates to imaging response to therapy
Provides a detailed discussion of different imaging modalities and individual organs
Focuses on analytical and clinical validation and serves as a guidebook to those seeking to develop new imaging standards
Radiologists, oncologists, imaging scientists, and computer scientists will find this book invaluable. It also serves as a comprehensive resource for teaching the fundamentals to trainees in radiology, medical physics, and imaging studies.
This book is dedicated to the quantitative imaging research efforts and memories of Laurence P. Clarke, NCI, and Edward F. Jackson, University of Wisconsin. Both were instrumental in the advancement of quantitative imaging throughout their careers, and the field is strong today because of their insight and leadership.
Acknowledgment
The editor acknowledges the enormous administrative effort from Dr. Kara Rader in making this book a reality.
Preface
In Nordstrom (2021), we presented the background and building blocks associated with quantitative imaging (QI) in the medical arena. The cornerstone to accepted utility for QI is the application of standards to the entire imaging process. Everything, from the data collection process through to final image display, must be under the control of standard operating procedures (SOPs); Chap. 2, by Kinahan et al., and Chap. 3, by Guimaraes, of Nordstrom (2021) emphasized this necessity. Standards are an important part of multisite clinical trials, where detailed protocols are established to harmonize results across the collaborating sites. Although, for these cases, compliance to SOPs is relatively easy to enforce, this is much less the case in standard-of-care community practice. Reluctance to comply to SOPs is a drawback to rapid acceptance of QI methods across all medical practice.
The tools typically used in QI were then presented. The RECIST method was an early contributor to the movement from qualitative evaluation of medical images toward providing some level of quantitative results. This longest-dimension measurement of tumors was successful in predicting patient outcome for some tumors, but ran into difficulty with more diffuse or fibrous images of tumors. However, other methods for extracting quantitative information from medical images have become popular and productive in recent years. For example, radiomics and artificial intelligence (AI) are now at the forefront of image analysis. The potential of these methods was presented in Nordstrom (2021), and is enlarged upon in various chapters of this book.
However, the ultimate value of these tools rests on their ability to determine exactly where the disease is located within the image, and to define its margins. The process of image segmentation is so critical to QI that it was given its own chapter in Nordstrom (2021). The process of defining the disease location precisely, with accurate boundaries, is more difficult than we might think. The boundaries of many tumors and organs can be indistinct, and can share tissue properties with the background. Partial volume effects can further blur these boundaries. Yet, the importance of making accurate boundary locations is critical to accurate QI methods that extract information for processing.
Nordstrom (2021) ends with the recognition that QI is not a single application of a specific method to a single image or series of medical images. It is a process of methods, each with its own set of SOPs and input/output formats. The creation of pipelines is a way to link methods together in a purpose-driven package. The pipeline concept allows for flexible selection and configuration of processing steps, bringing QI closer to user acceptability. It also allows for rapid and consistent processing of imaging in bulk, increasing the throughput of image processing in clinical trials.
This book takes the principles and caveats of QI presented in Nordstrom (2021) and applies them in a number of ways. First, QI is presented as part of the various imaging modalities used in the clinic. Magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and ultrasound (US) are clinical imaging methods where QI is making inroads. These imaging modalities are presented, with emphasis of the role of QI in each.
But emphasis on modalities is only one way to highlight the roles of QI in medicine. Looking at various organ sites to see how QI is applied, where the difficulties lie, and how they are being overcome, is yet another way of spotlighting the role of QI in medicine. Different chapters focus on the breast, brain, lung, bladder, and head and neck, to demonstrate the ways that QI is used in each.
Of course, it is not possible to separate completely the two approaches for discussing QI in medicine. A discussion of brain imaging will naturally bring up the various forms of MRI, and, conversely, a discussion of QI in MRI will focus, at least in part, on brain imaging. The goal in this book is to be as inclusive as possible of all aspects of QI in medicine, without worrying about the inevitable overlaps. As a result, the reader is encouraged to look at both the image modality chapters and the organ site chapters for a complete comprehension of QI in specific areas.
The lingering question regarding QI in medicine is, what is its clinical utility? Yet this question remains, despite all the definitions of QI and imaging biomarkers, all the presentations of algorithms and tools, and all the evidence that QI shows promise in a number of tumor sites. It is certainly one thing to demonstrate abilities in a research setting, but it is quite another to demonstrate clinical utility. There is no doubt that QI comes to the clinical environment carrying a lot of baggage, in the form of additional SOPs, quality assurance necessities, and reporting requirements. So, while there may be areas where the automation or semi-automation of image analysis can be attractive, the extra burden of standards and quality control can negate that attractiveness.
A constant issue from the radiologist community is concern over the validation of QI results. Without robust validation of algorithms, the weight of procedures and requirements associated with QI will be greater than the promise of more efficient clinical decision support. This is especially true when advancing AI or deep learning methods that are not supported by physiologic or metabolic models of disease. After all, in the words of Arthur C. Clarke, “Any sufficiently complex technology is indistinguishable from magic,” and radiologists are not going to begin relying on magic for patient diagnoses. This means that QI must prove itself through the process of validation in clinical trials.
To date, QI has established a firm foothold in clinical trial decision support. It will not go away. The question is, how rapidly will it be able to grow and expand in the clinical environment. This book, focusing on the applications of QI, is a strong indication that, although the acceptance of QI methods may be slow, there is steady progress in that direction.
References
Acronyms and Abbreviations
Acronym or Abbreviation . | Meaning . | Found in Chapter . |
---|---|---|
–N(CH3)3 | trimethylamine | 7 |
[13C]-MRS | carbon-13 magnetic resonance spectroscopy | 7 |
[18F]FDG | [fluorine-18] fluorodeoxyglucose | 2, 5, 6, 8, 11 |
[18F]FDHT | [fluorine-18] fluorodihydrotestosterone | 2 |
[18F]FES | [fluorine-18] fluoroestradiol | 2, 6, 11 |
[18F]FLT | 3ʹ-deoxy-3ʹ-[fluorine-18] fluorothymidine | 2, 5, 6, 7 |
[18F]FMISO | [fluorine-18] fluoromisonidazole | 7, 11 |
1D | one-dimensional | 9 |
[1H]-MRS | proton (hydrogen-1 nucleus) magnetic resonance spectroscopy | 7 |
2CXM | two-compartment exchange model | 10 |
2D | two-dimensional | 2, 9 |
2-HG | 2-hydroxyglutarate | 7 |
3D | three-dimensional | 2, 9 |
Ab-MRI | abbreviated-MRI | 6 |
AC | acoustic concentration | 4 |
ACR | American College of Radiology | 4, 6 |
ACRIN | American College of Radiology Imaging Network | 1, 6, 12 |
AD | axial diffusivity | 7 |
ADC | apparent diffusion coefficient | 1, 5, 7, 10 |
ADT | androgen deprivation therapy | 2 |
AI | artificial intelligence | 1, 2, 3, 5, 8, 13 |
AI-CALS | auto-initiated cascaded level set | 9 |
AIF | arterial input function | 1 |
AK | axial kurtosis | 7 |
Ala | alanine | 7 |
ALK | anaplastic lymphoma kinase | 8 |
ANOVA | analysis of variance | 12 |
ARFI | acoustic radiation force impulses | 4 |
ASL | arterial spin labeling | 1, 7 |
ATP | adenosine triphosphate | 7 |
ATS | American Thoracic Society | 8 |
AUROC | area under the receiver operating curve | 1, 2, 4, 8, 9, 18 |
BAC | bronchioalveolar cancer | 2 |
BBB | blood–brain barrier | 1, 7 |
BGO | bismuth germanate | 2 |
BI-RADS | (American College of Radiology) Breast Imaging Reporting and Data System | 1, 6, 7 |
BPE | background parenchymal enhancement | 6 |
BPNN | back propagating neural network | 9 |
BRATS | brain tumor image segmentation | 1 |
BrICS | brain imaging collaboration suite | 7 |
BrICS-LIT | brain imaging collaboration suite's longitudinal image tracker | 7 |
BSC | backscatter coefficient | 4 |
BT-RADS | brain tumor reporting and data system | 7 |
CA | contrast agent | 1, 6, 7, 10 |
CAD | computer-aided diagnosis | 1 |
CAF | Cancer associated fibroblast | 6 |
CASL | continuous arterial spin labeling | 7 |
CBF | cerebral blood flow | 1 |
CBV | cerebral blood volume | 1, 7 |
CCC | concordance correlation coefficient value | 8, 12 |
CCP | contour conjoint procedure | 8 |
CDRH | Center for Devices and Radiologic Health | 12 |
CDSS-S | Computer Decision Support System for Cancer Staging | 9 |
CDSS-T | Computer Decision Support System for Cancer Treatment Response | 9 |
CEST | chemical exchange-dependent saturation transfer | 7 |
CHARMED | composite hindered and restricted model of diffusion | 7 |
Cho | choline | 5, 7 |
CI | confidence intervals | 2, 4, 12 |
CLASS | conjoint level set analysis and segmentation system | 9 |
CLL | chronic lymphocytic leukemia | 2 |
CMR | complete metabolic response | 2 |
cNAWM | contralateral normal appearing white matter | 7 |
CNN | convolutional neural network | 5, 7, 8, 9 |
COU | context of use | 12 |
CR | complete response | 2, 7, 10 |
Cr | creatine | 7 |
CRI-RF | combined response index for radiomic features | 9 |
CRI-RF-DL | combined response index for radiomic features and deep learning | 9 |
CRI-RF-DL-EUA | combined response index for radiomic features and deep learning exam under anesthesia | 9 |
CRIs | combined response indices | 9 |
CRUK | Cancer Research United Kingdom | 12 |
CSF | cerebrospinal fluid | 1, 7 |
CT | computer tomography | 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13 |
CTRW | continuous time random walk | 7 |
CTU | computed tomography in urology | 9 |
CTV | clinical target volume | 5 |
CV | coefficient of variation | 8 |
DBT | digital breast tomosynthesis | 6 |
DCE | dynamic contrast-enhanced | 1, 7 |
DCE-MRI | dynamic contrast-enhanced magnetic resonance imaging | 7, 10, 11 |
DCIS | ductal carcinoma in situ | 6 |
DDC | distributed diffusion coefficient | 1 |
DDT | drug development tools | 12 |
DFOV | display field of view | 3 |
DICOM | digital imaging and communications in medicine | 2 |
DK | diffusion kurtosis | 1 |
DKI | diffusion kurtosis imaging | 7 |
DL | deep learning | 1, 3, 5, 6, 8, 9 |
DLBCL | diffuse large b-cell lymphoma | 2 |
DL-CNN | deep learning convolutional neural network | 9 |
DNA | deoxyribonucleic acid | 5 |
DOTATATE | dota tyrosine-3-octreotate | 5 |
DRO | digital reference object | 1, 8 |
DSC | dynamic susceptibility contrast | 1, 7 |
DTI | diffusion-tensor imaging | 1, 7 |
DWI | diffusion-weighted imaging | 1, 7, 10 |
DW-MRI | diffusion-weighted magnetic resonance imaging | 2, 10, 11 |
EAC | effective acoustic concentration | 4 |
EARL | European Association of Nuclear Medicine Research Limited | 2 |
EBV | Epstein–Barr virus | 10 |
ECM | extracellular matrix | 4, 6 |
ECOG-ACRIN | Eastern Cooperative Oncology Group American College of Radiology Imaging Network | 11 |
EDWP | energy-driven wavefront propagation | 9 |
EES | extravascular extracellular space | 1, 10 |
EFS | event-free survival | 2 |
EGFR | epidermal growth factor receptor | 7, 8, 10, 11, 12 |
eGFR | Estimated glomerular filtration rate | 12 |
EORTC | European Organization for Research and Treatment of Cancer | 2 |
EPI | echo planar imaging | 7, 9 |
EPSI | echo planar spectroscopic imaging | 7 |
ER | estrogen receptor | 6, 11 |
ERS | European Respiratory Society | 8 |
ESD | effective scatterer diameter | 4 |
ESS | effective scatterer size | 4 |
EUA | exam under anesthesia | 9 |
FA | fractional anisotropy | 1, 7 |
FACBC | 1-amino-3[18F]fluorocyclobutanne-1-carboxylic acid | 7 |
FAP | fibroblast activation protein | 6 |
FAPI | fibroblast activation protein inhibitor | 6 |
[18F]FCH | [fluorine-18] fluoromethyldimethyl-(2-hydrooxyethyl) ammonium chloride | 7 |
FDA | United States Food and Drug Administration | 2, 10, 12 |
FDG-PET | [fluorine-18]fluorodeoxyglucose positron emission tomography | 2, 7, 8, 10 |
FDG-PET/CT | [fluorine-18]fluorodeoxyglucose positron emission tomography with computed tomography | 5, 6, 11 |
FDG-SUV | [fluorine-18]fluorodeoxyglucose standard uptake value | 2 |
fDM | functional diffusion map | 1, 7 |
FES-PET | [fluorine-18] fluoroestradiol positron emission tomography | 11 |
FFDM | full-field digital mammography | 6, 14 |
FLAIR | fluid attenuated inversion recovery | 1, 7 |
FM | fractional motion | 7 |
FMISO-PET | [fluorine-18] fluoromisonidazole positron emission tomography | 7, 11 |
FNAC | fine-needle aspiration cytology | 10 |
FQP | full qualification package | 12 |
FTB | fractional tumor burden | 1 |
FTV | functional tumor volume | 1, 6 |
FWHM | full-width at half maximum | 2 |
FXR | fast exchange regime model | 10 |
GABA | gamma aminobutyric acid | 7 |
GBCA | gadolinium-based contrast agent | 1, 7, 10 |
GBM | glioblastoma multiforme | 1, 7 |
GGO | ground glass opacity | 2 |
GLCM | gray level co-occurrence matrix | 8 |
Glu | glutamate | 7 |
GPC | glycerophosphocholine | 7 |
GPU | glycerophosphocholine unit | 5 |
GRAPPA | generalized autocalibrating partially parallel acquisitions | 7 |
GRE | gradient echo | 1 |
GRE EPI | gradient echo echo planar imaging | 1 |
GTV | gross tumor volume | 5, 9 |
GUI | graphical user interface | 9 |
HER2 | human epidermal growth factor receptor 2 | 2, 6, 10, 11 |
HIF-1a | hypoxia inducible factor 1 alpha | 7, 10 |
HNSCC | head and neck squamous cell carcinoma | 10 |
HPV | human papillomavirus | 8, 10 |
HR | hazard ratio | 2 |
HU | Hounsfield unit | 3, 12 |
IBEX | imaging biomarker explorer | 8 |
IBSI | imaging biomarker standardization initiative | 8 |
ICS | intracellular space | 10 |
IDH | isocitrate dehydrogenase | 7 |
IHC | immunohistochemistry | 11 |
IHT | intensity harmonization technique | 1 |
IMRF | International Medical Device Regulators Forum | 12 |
IMRT | intensity-modulated radiation therapy | 5, 10 |
IOM | Institute of Medicine | 12 |
I-SPY | investigation of serial studies to predict your therapeutic response with imaging and molecular analysis | 1, 11 |
ITK-Snap | insight toolkit with semi-automatic segmentation | 8 |
IVIM | intravoxel incoherent motion | 1, 7, 10 |
Ki-67 | protein encoded by mki67 gene, a cellular marker for proliferation | 10 |
KRAS | a gene providing instructions for making the kras protein that instructs cells to grow and divide | 8 |
kVp | kilovoltage peak | 6, 9, 12 |
Lac | lactate | 7 |
LCR | local contour refinement | 9 |
LDA | linear discriminant analysis | 9 |
L-DOPA | l-3,4-dihydroxyphenylalanine | 7 |
L-FET | o-(2-[18F]fluoroeethyl)-l-tyrosine | 7 |
LGG | low-grade glioma | 7 |
LIDC | lung image database consortium | 8 |
LLoQ/ULoQ | lower/upper limit of quantification | 12 |
LOA | limit of agreement | 12 |
LOI | letter of intent | 12 |
LSO | lutetium oxyorthosilicate | 2 |
MAA | microaggregated albumid | 2 |
MD | mean diffusivity | 1, 7 |
MDP | methylene diphosphonate | 2, 11 |
METAVIR | a semi-quantitative classification system to characterize and predict chronic liver disease progression | 4 |
MET-PET | [11C]methionine positron emission tomography | 7 |
MGR | model guided refinement | 9 |
mI | myo-inositol | 7 |
MK | mean kurtosis | 7 |
MR | magnetic resonance | 1, 2 5, 7, 8, 10, 11, 12 |
MRE | magnetic resonance-based elastography | 4 |
MRI | magnetic resonance imaging | 1, 4, 6, 7, 8, 9, 10, 11 |
MRS | magnetic resonance spectroscopy | 6, 7, 11 |
MRSI | magnetic resonance spectroscopic imaging | 7 |
MSD | maximum signal drop | 1 |
MSE | mean square error | 12 |
MTT | mean transit time | 1, 7 |
MTV | metabolic tumor volume | 2 |
MVAC | methotrexate, vinblastine, doxorubicin, and cisplatin | 9 |
N0 neck | without evidence of lymph node involvement | 12 |
NAA | N-acetylaspartate | 5, 7 |
NAAG | N-acetylaspartate glutamate | 7 |
NAC | neoadjuvant chemotherapy | 6, 9 |
Naf PET | sodium fluoride positron emission tomography | 2 |
NAFLD | non-alcoholic fatty liver disease | 4 |
NC | an area without contrast | 9 |
NCCN | National Comprehensive Cancer Network | 2 |
NCI | National Cancer Institute | 11, 13 |
nCRT | neoadjuvant chemoradiotherapy | 2 |
NCTN | national clinical trial network | 2 |
NEI | negative enhancement integral | 1 |
NEMA | National Electrical Manufacturers Association | 2 |
NEMA NU-2 | National Electrical Manufacturers Association Nu2 Phantom | 2 |
NeoALTTO | neoadjuvant lapatinib and/or trastuzumab treatment option clinical trial | 11 |
NET | neuroendocrine tumors | 2 |
NG-IVIM-DW | non-Gaussian intervoxel incoherent motion in diffusion-weighted imaging | 10 |
NHL | non-Hodgkin lymphoma | 2 |
NMR | nuclear magnetic resonance | 7 |
NN | neural network | 9 |
NPC | nasopharyngeal carcinoma | 10 |
NPL | nasopharyngeal lymphoma | 10 |
NPV | negative predictive value | 2, 6, 12 |
NSCLC | non-small cell lung cancer | 2, 3, 8, 12 |
NTCP | normal tissue complication probability | 2, 5 |
OS | overall survival | 2, 8, 11 |
p16 | protein that slows cell division by slowing progression of the cell cycle | 10 |
p53 | a gene that codes for protein that regulates cell cycle and functions as a tumor suppressor | 10 |
PASL | pulsed arterial spin labeling | 7 |
PC | phosphocholine | 7 |
pCASL | pseudo continuous arterial spin labeling | 7 |
pCR | pathologic complete response | 2, 6, 11 |
PD | progressive disease | 7 |
PD-L1 | programmed death ligand 1 | 8 |
PEM | positron emission mammography | 6 |
PER | parameter estimation region | 4 |
PERCIST | positron emission response criteria in solid tumors | 2, 6, 10 |
PET/CT | positron emission tomography with computed tomography | 2, 6, 10, 11, 12 |
PET/MRI | positron emission tomography with magnetic resonance imaging | 2 |
PET2 | positron emission tomography done after cycle 2 | 2 |
PET4 | positron emission tomography done after cycle 4 | 2 |
PETAL | positron emission tomography guided therapy of aggressive non-Hodgkin's lymphoma | 2 |
PFS | progression-free survival | 2, 7, 8, 9, 11 |
PH | peak height | 1 |
PI | pulsatility index | 4 |
PIRADS | prostate imaging and reporting data systems | 1 |
PK | pharmacokinetic | 1, 6 |
PMD | progressive metabolic disease | 2 |
PMR | partial metabolic response | 2 |
pNAWM | perilesional normal appearing white matter tissue | 7 |
PR | partial response | 2, 7 |
PRESS | point resolved spectroscopy | 7 |
PSA | prostate cancer antigen | 2 |
PSF | point spread function | 2 |
PSMA | prostate specific membrane antigen | 2, 5 |
PSMA-TV | prostate specific membrane antigen tumor | 2 |
PSR | percent signal recovery | 1, 7 |
PTEN | agene located on the chromosome band 10q23 | 7 |
PTV | planning target volume | 2, 5 |
PWI | perfusion-weighted imaging | 1, 7 |
pWM | perilesional white matter | 7 |
QA/QC | quality assurance/quality control | 12 |
QIB | quantitative imaging biomarker | 4, 8, 10, 11, 12 |
QIBA | Quantitative Imaging Biomarker Alliance | 2, 4, 12 |
QIBC | quantitative image analysis tool for bladder cancer | 9 |
QIN | Quantitative Imaging Network | 8, 11, 13 |
QUS | quantitative ultrasound | 4 |
R | fractional order calculus | 7 |
R2 | relaxation rate | 1, 12 |
RAD | radiation absorbed dose | 2 |
RAF | random forest | 8, 9 |
RANO | response assessment in neuro-oncology | 7 |
RC | repeatability coefficient | 2, 12 |
RCB | residual cancer burden | 6 |
rCBF | relative cerebral blood flow | 7 |
rCBV | relative cerebral blood volume | 1, 7 |
R-CHOP | drugs in combination: rituximab, cyctophosphamide, hydroxydaunomycin, oncovin, and prednisone | 2 |
RD | radial diffusivity | 7 |
RDC | reproducibility coefficient | 12 |
RECIST | response evaluation criteria in solid tumors | 7, 8, 9, 11, 12, 13 |
REDCap | research electronic data capture | 7 |
REMARK | Reporting Recommendations for Tumor Marker Prognostic Studies | 11, 12 |
RF | radiofrequency | 1, 4, 5, 7 |
RFs | radiomic features | 1, 3, 6, 8, 9 |
RFA | radiofrequency ablation | 8 |
RF-ROI | radiomic features for paired regions of interest | 9 |
RFS | recurrence-free survival | 6, 11 |
RF SL | radiomic features segmented lesions | 9 |
RI | resistivity index | 4 |
RIDER | reference image database to evaluate therapy response | 8 |
RK | radial kurtosis | 7 |
ROC | receiver operating characteristic or curve | 4, 8, 9, 12 |
ROI | region of interest | 1, 3, 4, 6, 9 |
RPM | reference phantom method | 4 |
RPT | radiopharmaceutical therapy | 5 |
RSI | restricted spectrum imaging | 1, 7 |
RSNA | Radiological Society of North America | 12 |
RT | radiation therapy | 7 |
SAGE | spin and gradient echo | 1 |
SaMD | software and medical device | 12 |
SAS | spacing among scatterers, also referred to as mean scatterer spacing | 4 |
SCC | squamous cell carcinoma | 10 |
SCLC | small cell liver cancer | 2, 8 |
SD | stable disease | 7 |
SE | spin-echo | 1, 7 |
SE-EPI | spin-echo echo planar imaging | 1 |
SEER | surveillance, epidemiology, and end results | 7 |
SENSE | sensitivity encoding | 7 |
SER | signal enhancement ratio | 1 |
SMD | stable metabolic disease | 2 |
sMRI | spectroscopic magnetic resonance imaging | 7 |
SNR | signal-to-noise ratio | 1, 4, 7 |
SPECT | single photon emission computed tomography | 2 |
SPECT/CT | single photon emission computed tomography with computed tomography | 5 |
SPGR | spoiled gradient echo | 1, 10 |
sRCBV | standardized relative cerebral blood volume | 1 |
SRE | skeletal related event | 11 |
SRS | stereotactic radiosurgery | 5 |
SSA | singular spectrum analysis | 4 |
SSE | spatial–spectral encoding | 7 |
SS-EPI | single shot echo planar imaging | 10 |
SUL | standard uptake lean (body mass) | 2 |
SUR | standard uptake ratio | 2 |
SUV | standard uptake value | 2, 6, 8, 12 |
SVM | support vector machine | 9 |
SWEI | shear wave elasticity imaging | 4 |
T/WM | tumor to white matter ratio | 2 |
T0 | total response to therapy: no disease | 9 |
T1 | stage 1 of disease | 9 |
T1 | time to reach 2/3 of equilibrium magnetization along z-axis | 7, 8, 9, 10, 12 |
T2 | transverse relaxation time | 1, 7, 12 |
T2 | stage 2 of disease | 9 |
T2* | observed or effective transverse relaxation time | 1, 7 |
TB | tuberculosis | 2 |
TBR | target to blood pool ratio | 2, 11 |
TCM | tube current modulation | 3 |
TCP | tumor control probability | 5 |
TE | echo time | 1, 7 |
Ti-RADS | thyroid imaging reporting and data system | 10 |
TK1 | thymidine kinase | 7 |
TLF | total lesion fluoride uptake | 2 |
TLG | total lesion glycolysis | 2 |
TL-PSMA | total lesion prostate specific membrane antigen | 2 |
TLU | total lesion uptake | 2 |
TMS | tetramethylsilane | 7 |
TMTV | total metabolic tumor volume | 2 |
TNBC | triple negative breast cancer | 2 |
TNM | tumor, node, metastasis | 8 |
TOF | time of flight | 2, 4 |
TRG | total lesion glycolysis | 2 |
TTP | time to peak | 1 |
TTP | time to perfusion | 10 |
TURBT | transurethral resection of bladder tumor | 9 |
UDFF | ultrasound-derived fat fraction | 4 |
U-DL | U-Net-based deep learning | 9 |
UPICT | uniform protocols for imaging in clinical trials | 2 |
VEGF | vascular endothelial growth factor | 7, 10 |
VERDICT | vascular, extracellular, and restricted diffusion for cytometry in tumors | 7 |
VMAT | volumetric modulated arc therapy | 5 |
VOI | volume of interest | 2, 7 |
WHO | World Health Organization | 9 |
WOLD | a time series decomposition theorem | 4 |
Acronym or Abbreviation . | Meaning . | Found in Chapter . |
---|---|---|
–N(CH3)3 | trimethylamine | 7 |
[13C]-MRS | carbon-13 magnetic resonance spectroscopy | 7 |
[18F]FDG | [fluorine-18] fluorodeoxyglucose | 2, 5, 6, 8, 11 |
[18F]FDHT | [fluorine-18] fluorodihydrotestosterone | 2 |
[18F]FES | [fluorine-18] fluoroestradiol | 2, 6, 11 |
[18F]FLT | 3ʹ-deoxy-3ʹ-[fluorine-18] fluorothymidine | 2, 5, 6, 7 |
[18F]FMISO | [fluorine-18] fluoromisonidazole | 7, 11 |
1D | one-dimensional | 9 |
[1H]-MRS | proton (hydrogen-1 nucleus) magnetic resonance spectroscopy | 7 |
2CXM | two-compartment exchange model | 10 |
2D | two-dimensional | 2, 9 |
2-HG | 2-hydroxyglutarate | 7 |
3D | three-dimensional | 2, 9 |
Ab-MRI | abbreviated-MRI | 6 |
AC | acoustic concentration | 4 |
ACR | American College of Radiology | 4, 6 |
ACRIN | American College of Radiology Imaging Network | 1, 6, 12 |
AD | axial diffusivity | 7 |
ADC | apparent diffusion coefficient | 1, 5, 7, 10 |
ADT | androgen deprivation therapy | 2 |
AI | artificial intelligence | 1, 2, 3, 5, 8, 13 |
AI-CALS | auto-initiated cascaded level set | 9 |
AIF | arterial input function | 1 |
AK | axial kurtosis | 7 |
Ala | alanine | 7 |
ALK | anaplastic lymphoma kinase | 8 |
ANOVA | analysis of variance | 12 |
ARFI | acoustic radiation force impulses | 4 |
ASL | arterial spin labeling | 1, 7 |
ATP | adenosine triphosphate | 7 |
ATS | American Thoracic Society | 8 |
AUROC | area under the receiver operating curve | 1, 2, 4, 8, 9, 18 |
BAC | bronchioalveolar cancer | 2 |
BBB | blood–brain barrier | 1, 7 |
BGO | bismuth germanate | 2 |
BI-RADS | (American College of Radiology) Breast Imaging Reporting and Data System | 1, 6, 7 |
BPE | background parenchymal enhancement | 6 |
BPNN | back propagating neural network | 9 |
BRATS | brain tumor image segmentation | 1 |
BrICS | brain imaging collaboration suite | 7 |
BrICS-LIT | brain imaging collaboration suite's longitudinal image tracker | 7 |
BSC | backscatter coefficient | 4 |
BT-RADS | brain tumor reporting and data system | 7 |
CA | contrast agent | 1, 6, 7, 10 |
CAD | computer-aided diagnosis | 1 |
CAF | Cancer associated fibroblast | 6 |
CASL | continuous arterial spin labeling | 7 |
CBF | cerebral blood flow | 1 |
CBV | cerebral blood volume | 1, 7 |
CCC | concordance correlation coefficient value | 8, 12 |
CCP | contour conjoint procedure | 8 |
CDRH | Center for Devices and Radiologic Health | 12 |
CDSS-S | Computer Decision Support System for Cancer Staging | 9 |
CDSS-T | Computer Decision Support System for Cancer Treatment Response | 9 |
CEST | chemical exchange-dependent saturation transfer | 7 |
CHARMED | composite hindered and restricted model of diffusion | 7 |
Cho | choline | 5, 7 |
CI | confidence intervals | 2, 4, 12 |
CLASS | conjoint level set analysis and segmentation system | 9 |
CLL | chronic lymphocytic leukemia | 2 |
CMR | complete metabolic response | 2 |
cNAWM | contralateral normal appearing white matter | 7 |
CNN | convolutional neural network | 5, 7, 8, 9 |
COU | context of use | 12 |
CR | complete response | 2, 7, 10 |
Cr | creatine | 7 |
CRI-RF | combined response index for radiomic features | 9 |
CRI-RF-DL | combined response index for radiomic features and deep learning | 9 |
CRI-RF-DL-EUA | combined response index for radiomic features and deep learning exam under anesthesia | 9 |
CRIs | combined response indices | 9 |
CRUK | Cancer Research United Kingdom | 12 |
CSF | cerebrospinal fluid | 1, 7 |
CT | computer tomography | 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13 |
CTRW | continuous time random walk | 7 |
CTU | computed tomography in urology | 9 |
CTV | clinical target volume | 5 |
CV | coefficient of variation | 8 |
DBT | digital breast tomosynthesis | 6 |
DCE | dynamic contrast-enhanced | 1, 7 |
DCE-MRI | dynamic contrast-enhanced magnetic resonance imaging | 7, 10, 11 |
DCIS | ductal carcinoma in situ | 6 |
DDC | distributed diffusion coefficient | 1 |
DDT | drug development tools | 12 |
DFOV | display field of view | 3 |
DICOM | digital imaging and communications in medicine | 2 |
DK | diffusion kurtosis | 1 |
DKI | diffusion kurtosis imaging | 7 |
DL | deep learning | 1, 3, 5, 6, 8, 9 |
DLBCL | diffuse large b-cell lymphoma | 2 |
DL-CNN | deep learning convolutional neural network | 9 |
DNA | deoxyribonucleic acid | 5 |
DOTATATE | dota tyrosine-3-octreotate | 5 |
DRO | digital reference object | 1, 8 |
DSC | dynamic susceptibility contrast | 1, 7 |
DTI | diffusion-tensor imaging | 1, 7 |
DWI | diffusion-weighted imaging | 1, 7, 10 |
DW-MRI | diffusion-weighted magnetic resonance imaging | 2, 10, 11 |
EAC | effective acoustic concentration | 4 |
EARL | European Association of Nuclear Medicine Research Limited | 2 |
EBV | Epstein–Barr virus | 10 |
ECM | extracellular matrix | 4, 6 |
ECOG-ACRIN | Eastern Cooperative Oncology Group American College of Radiology Imaging Network | 11 |
EDWP | energy-driven wavefront propagation | 9 |
EES | extravascular extracellular space | 1, 10 |
EFS | event-free survival | 2 |
EGFR | epidermal growth factor receptor | 7, 8, 10, 11, 12 |
eGFR | Estimated glomerular filtration rate | 12 |
EORTC | European Organization for Research and Treatment of Cancer | 2 |
EPI | echo planar imaging | 7, 9 |
EPSI | echo planar spectroscopic imaging | 7 |
ER | estrogen receptor | 6, 11 |
ERS | European Respiratory Society | 8 |
ESD | effective scatterer diameter | 4 |
ESS | effective scatterer size | 4 |
EUA | exam under anesthesia | 9 |
FA | fractional anisotropy | 1, 7 |
FACBC | 1-amino-3[18F]fluorocyclobutanne-1-carboxylic acid | 7 |
FAP | fibroblast activation protein | 6 |
FAPI | fibroblast activation protein inhibitor | 6 |
[18F]FCH | [fluorine-18] fluoromethyldimethyl-(2-hydrooxyethyl) ammonium chloride | 7 |
FDA | United States Food and Drug Administration | 2, 10, 12 |
FDG-PET | [fluorine-18]fluorodeoxyglucose positron emission tomography | 2, 7, 8, 10 |
FDG-PET/CT | [fluorine-18]fluorodeoxyglucose positron emission tomography with computed tomography | 5, 6, 11 |
FDG-SUV | [fluorine-18]fluorodeoxyglucose standard uptake value | 2 |
fDM | functional diffusion map | 1, 7 |
FES-PET | [fluorine-18] fluoroestradiol positron emission tomography | 11 |
FFDM | full-field digital mammography | 6, 14 |
FLAIR | fluid attenuated inversion recovery | 1, 7 |
FM | fractional motion | 7 |
FMISO-PET | [fluorine-18] fluoromisonidazole positron emission tomography | 7, 11 |
FNAC | fine-needle aspiration cytology | 10 |
FQP | full qualification package | 12 |
FTB | fractional tumor burden | 1 |
FTV | functional tumor volume | 1, 6 |
FWHM | full-width at half maximum | 2 |
FXR | fast exchange regime model | 10 |
GABA | gamma aminobutyric acid | 7 |
GBCA | gadolinium-based contrast agent | 1, 7, 10 |
GBM | glioblastoma multiforme | 1, 7 |
GGO | ground glass opacity | 2 |
GLCM | gray level co-occurrence matrix | 8 |
Glu | glutamate | 7 |
GPC | glycerophosphocholine | 7 |
GPU | glycerophosphocholine unit | 5 |
GRAPPA | generalized autocalibrating partially parallel acquisitions | 7 |
GRE | gradient echo | 1 |
GRE EPI | gradient echo echo planar imaging | 1 |
GTV | gross tumor volume | 5, 9 |
GUI | graphical user interface | 9 |
HER2 | human epidermal growth factor receptor 2 | 2, 6, 10, 11 |
HIF-1a | hypoxia inducible factor 1 alpha | 7, 10 |
HNSCC | head and neck squamous cell carcinoma | 10 |
HPV | human papillomavirus | 8, 10 |
HR | hazard ratio | 2 |
HU | Hounsfield unit | 3, 12 |
IBEX | imaging biomarker explorer | 8 |
IBSI | imaging biomarker standardization initiative | 8 |
ICS | intracellular space | 10 |
IDH | isocitrate dehydrogenase | 7 |
IHC | immunohistochemistry | 11 |
IHT | intensity harmonization technique | 1 |
IMRF | International Medical Device Regulators Forum | 12 |
IMRT | intensity-modulated radiation therapy | 5, 10 |
IOM | Institute of Medicine | 12 |
I-SPY | investigation of serial studies to predict your therapeutic response with imaging and molecular analysis | 1, 11 |
ITK-Snap | insight toolkit with semi-automatic segmentation | 8 |
IVIM | intravoxel incoherent motion | 1, 7, 10 |
Ki-67 | protein encoded by mki67 gene, a cellular marker for proliferation | 10 |
KRAS | a gene providing instructions for making the kras protein that instructs cells to grow and divide | 8 |
kVp | kilovoltage peak | 6, 9, 12 |
Lac | lactate | 7 |
LCR | local contour refinement | 9 |
LDA | linear discriminant analysis | 9 |
L-DOPA | l-3,4-dihydroxyphenylalanine | 7 |
L-FET | o-(2-[18F]fluoroeethyl)-l-tyrosine | 7 |
LGG | low-grade glioma | 7 |
LIDC | lung image database consortium | 8 |
LLoQ/ULoQ | lower/upper limit of quantification | 12 |
LOA | limit of agreement | 12 |
LOI | letter of intent | 12 |
LSO | lutetium oxyorthosilicate | 2 |
MAA | microaggregated albumid | 2 |
MD | mean diffusivity | 1, 7 |
MDP | methylene diphosphonate | 2, 11 |
METAVIR | a semi-quantitative classification system to characterize and predict chronic liver disease progression | 4 |
MET-PET | [11C]methionine positron emission tomography | 7 |
MGR | model guided refinement | 9 |
mI | myo-inositol | 7 |
MK | mean kurtosis | 7 |
MR | magnetic resonance | 1, 2 5, 7, 8, 10, 11, 12 |
MRE | magnetic resonance-based elastography | 4 |
MRI | magnetic resonance imaging | 1, 4, 6, 7, 8, 9, 10, 11 |
MRS | magnetic resonance spectroscopy | 6, 7, 11 |
MRSI | magnetic resonance spectroscopic imaging | 7 |
MSD | maximum signal drop | 1 |
MSE | mean square error | 12 |
MTT | mean transit time | 1, 7 |
MTV | metabolic tumor volume | 2 |
MVAC | methotrexate, vinblastine, doxorubicin, and cisplatin | 9 |
N0 neck | without evidence of lymph node involvement | 12 |
NAA | N-acetylaspartate | 5, 7 |
NAAG | N-acetylaspartate glutamate | 7 |
NAC | neoadjuvant chemotherapy | 6, 9 |
Naf PET | sodium fluoride positron emission tomography | 2 |
NAFLD | non-alcoholic fatty liver disease | 4 |
NC | an area without contrast | 9 |
NCCN | National Comprehensive Cancer Network | 2 |
NCI | National Cancer Institute | 11, 13 |
nCRT | neoadjuvant chemoradiotherapy | 2 |
NCTN | national clinical trial network | 2 |
NEI | negative enhancement integral | 1 |
NEMA | National Electrical Manufacturers Association | 2 |
NEMA NU-2 | National Electrical Manufacturers Association Nu2 Phantom | 2 |
NeoALTTO | neoadjuvant lapatinib and/or trastuzumab treatment option clinical trial | 11 |
NET | neuroendocrine tumors | 2 |
NG-IVIM-DW | non-Gaussian intervoxel incoherent motion in diffusion-weighted imaging | 10 |
NHL | non-Hodgkin lymphoma | 2 |
NMR | nuclear magnetic resonance | 7 |
NN | neural network | 9 |
NPC | nasopharyngeal carcinoma | 10 |
NPL | nasopharyngeal lymphoma | 10 |
NPV | negative predictive value | 2, 6, 12 |
NSCLC | non-small cell lung cancer | 2, 3, 8, 12 |
NTCP | normal tissue complication probability | 2, 5 |
OS | overall survival | 2, 8, 11 |
p16 | protein that slows cell division by slowing progression of the cell cycle | 10 |
p53 | a gene that codes for protein that regulates cell cycle and functions as a tumor suppressor | 10 |
PASL | pulsed arterial spin labeling | 7 |
PC | phosphocholine | 7 |
pCASL | pseudo continuous arterial spin labeling | 7 |
pCR | pathologic complete response | 2, 6, 11 |
PD | progressive disease | 7 |
PD-L1 | programmed death ligand 1 | 8 |
PEM | positron emission mammography | 6 |
PER | parameter estimation region | 4 |
PERCIST | positron emission response criteria in solid tumors | 2, 6, 10 |
PET/CT | positron emission tomography with computed tomography | 2, 6, 10, 11, 12 |
PET/MRI | positron emission tomography with magnetic resonance imaging | 2 |
PET2 | positron emission tomography done after cycle 2 | 2 |
PET4 | positron emission tomography done after cycle 4 | 2 |
PETAL | positron emission tomography guided therapy of aggressive non-Hodgkin's lymphoma | 2 |
PFS | progression-free survival | 2, 7, 8, 9, 11 |
PH | peak height | 1 |
PI | pulsatility index | 4 |
PIRADS | prostate imaging and reporting data systems | 1 |
PK | pharmacokinetic | 1, 6 |
PMD | progressive metabolic disease | 2 |
PMR | partial metabolic response | 2 |
pNAWM | perilesional normal appearing white matter tissue | 7 |
PR | partial response | 2, 7 |
PRESS | point resolved spectroscopy | 7 |
PSA | prostate cancer antigen | 2 |
PSF | point spread function | 2 |
PSMA | prostate specific membrane antigen | 2, 5 |
PSMA-TV | prostate specific membrane antigen tumor | 2 |
PSR | percent signal recovery | 1, 7 |
PTEN | agene located on the chromosome band 10q23 | 7 |
PTV | planning target volume | 2, 5 |
PWI | perfusion-weighted imaging | 1, 7 |
pWM | perilesional white matter | 7 |
QA/QC | quality assurance/quality control | 12 |
QIB | quantitative imaging biomarker | 4, 8, 10, 11, 12 |
QIBA | Quantitative Imaging Biomarker Alliance | 2, 4, 12 |
QIBC | quantitative image analysis tool for bladder cancer | 9 |
QIN | Quantitative Imaging Network | 8, 11, 13 |
QUS | quantitative ultrasound | 4 |
R | fractional order calculus | 7 |
R2 | relaxation rate | 1, 12 |
RAD | radiation absorbed dose | 2 |
RAF | random forest | 8, 9 |
RANO | response assessment in neuro-oncology | 7 |
RC | repeatability coefficient | 2, 12 |
RCB | residual cancer burden | 6 |
rCBF | relative cerebral blood flow | 7 |
rCBV | relative cerebral blood volume | 1, 7 |
R-CHOP | drugs in combination: rituximab, cyctophosphamide, hydroxydaunomycin, oncovin, and prednisone | 2 |
RD | radial diffusivity | 7 |
RDC | reproducibility coefficient | 12 |
RECIST | response evaluation criteria in solid tumors | 7, 8, 9, 11, 12, 13 |
REDCap | research electronic data capture | 7 |
REMARK | Reporting Recommendations for Tumor Marker Prognostic Studies | 11, 12 |
RF | radiofrequency | 1, 4, 5, 7 |
RFs | radiomic features | 1, 3, 6, 8, 9 |
RFA | radiofrequency ablation | 8 |
RF-ROI | radiomic features for paired regions of interest | 9 |
RFS | recurrence-free survival | 6, 11 |
RF SL | radiomic features segmented lesions | 9 |
RI | resistivity index | 4 |
RIDER | reference image database to evaluate therapy response | 8 |
RK | radial kurtosis | 7 |
ROC | receiver operating characteristic or curve | 4, 8, 9, 12 |
ROI | region of interest | 1, 3, 4, 6, 9 |
RPM | reference phantom method | 4 |
RPT | radiopharmaceutical therapy | 5 |
RSI | restricted spectrum imaging | 1, 7 |
RSNA | Radiological Society of North America | 12 |
RT | radiation therapy | 7 |
SAGE | spin and gradient echo | 1 |
SaMD | software and medical device | 12 |
SAS | spacing among scatterers, also referred to as mean scatterer spacing | 4 |
SCC | squamous cell carcinoma | 10 |
SCLC | small cell liver cancer | 2, 8 |
SD | stable disease | 7 |
SE | spin-echo | 1, 7 |
SE-EPI | spin-echo echo planar imaging | 1 |
SEER | surveillance, epidemiology, and end results | 7 |
SENSE | sensitivity encoding | 7 |
SER | signal enhancement ratio | 1 |
SMD | stable metabolic disease | 2 |
sMRI | spectroscopic magnetic resonance imaging | 7 |
SNR | signal-to-noise ratio | 1, 4, 7 |
SPECT | single photon emission computed tomography | 2 |
SPECT/CT | single photon emission computed tomography with computed tomography | 5 |
SPGR | spoiled gradient echo | 1, 10 |
sRCBV | standardized relative cerebral blood volume | 1 |
SRE | skeletal related event | 11 |
SRS | stereotactic radiosurgery | 5 |
SSA | singular spectrum analysis | 4 |
SSE | spatial–spectral encoding | 7 |
SS-EPI | single shot echo planar imaging | 10 |
SUL | standard uptake lean (body mass) | 2 |
SUR | standard uptake ratio | 2 |
SUV | standard uptake value | 2, 6, 8, 12 |
SVM | support vector machine | 9 |
SWEI | shear wave elasticity imaging | 4 |
T/WM | tumor to white matter ratio | 2 |
T0 | total response to therapy: no disease | 9 |
T1 | stage 1 of disease | 9 |
T1 | time to reach 2/3 of equilibrium magnetization along z-axis | 7, 8, 9, 10, 12 |
T2 | transverse relaxation time | 1, 7, 12 |
T2 | stage 2 of disease | 9 |
T2* | observed or effective transverse relaxation time | 1, 7 |
TB | tuberculosis | 2 |
TBR | target to blood pool ratio | 2, 11 |
TCM | tube current modulation | 3 |
TCP | tumor control probability | 5 |
TE | echo time | 1, 7 |
Ti-RADS | thyroid imaging reporting and data system | 10 |
TK1 | thymidine kinase | 7 |
TLF | total lesion fluoride uptake | 2 |
TLG | total lesion glycolysis | 2 |
TL-PSMA | total lesion prostate specific membrane antigen | 2 |
TLU | total lesion uptake | 2 |
TMS | tetramethylsilane | 7 |
TMTV | total metabolic tumor volume | 2 |
TNBC | triple negative breast cancer | 2 |
TNM | tumor, node, metastasis | 8 |
TOF | time of flight | 2, 4 |
TRG | total lesion glycolysis | 2 |
TTP | time to peak | 1 |
TTP | time to perfusion | 10 |
TURBT | transurethral resection of bladder tumor | 9 |
UDFF | ultrasound-derived fat fraction | 4 |
U-DL | U-Net-based deep learning | 9 |
UPICT | uniform protocols for imaging in clinical trials | 2 |
VEGF | vascular endothelial growth factor | 7, 10 |
VERDICT | vascular, extracellular, and restricted diffusion for cytometry in tumors | 7 |
VMAT | volumetric modulated arc therapy | 5 |
VOI | volume of interest | 2, 7 |
WHO | World Health Organization | 9 |
WOLD | a time series decomposition theorem | 4 |
Contributors
Reinhard R. Beichel
Professor, Department of ECE, University of Iowa, Iowa City, IA
John M. Buatti
Department of Radiaton Oncoogy, University of Iowa, Iowa City, IA
Heang-Ping Chan
Paul L. Carson Collegiate Professor, Radiology, Director, CAD-Ai Research Laboratory, University of Michigan, Ann Arbor, MI
Jana Delfino
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD
Laurent Dercle
Columbia University, Department of Radiology, New York, NY
Marios A. Gavrielides
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD (currently with AstraZeneca, Gaithersburg, MD)
Mohammed Goryawala
Research Assistant Professor, Department of Radiology, University of Miami, Miami, FL
Lubomir Hadjiyski
Professor, Radiology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
Timothy J. Hall
Department of Medical Physics, University of Wisconsin-Madison, Madison, WI
Deep K. Hathi
University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA, USA
Vaios Hatzoglou
Memorial Sloan Kettering Cancer Center, New York, NY
Nola M. Hylton
University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA, USA
Ella F. Jones
University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA, USA
Qin Li
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD (currently with AstraZeneca, Waltham, MA)
Martin A. Lodge
Department of Radiology, Johns Hopkins University, Baltimore, MD
David Mankoff
Department of Radiology, University of Pennsylvania, Philadelphia, PA
Michael McNitt-Gray
Director, Physics and Biology in Medicine Graduate Program, Professor, Department of Radiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA
Robert J. Nordstrom
Director, Quantitative Imaging Network, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD
Ramesh Paudyal
Memorial Sloan Kettering Cancer Center, New York, NY
Nicholas Petrick
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD
Ivan M. Rosado-Mendez
Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
Ravi Samala
Adjunct Research Assistant Professor, Radiology, University of Michigan, Ann Arbor, MI
Kathleen M. Schmainda
Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI
Lawrence H. Schwartz
Department of Radiology, Columbia University, New York, NY
Akash Deelip Shah
Memorial Sloan Kettering Cancer Center, New York, NY
Hyunsuk Shim
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA
Amita Shukla-Dave
Memorial Sloan Kettering Cancer Center, New York, NY
Richard L. Wahl
Chairman, Department of Radiology, Washington University, St. Louis, MO
Brent Weinberg
Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA
Binsheng Zhao
Columbia University, Department of Radiology, New York, NY